nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR1—cleft lip	0.00116	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—FGFR2—cleft lip	0.00115	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FGFR2—cleft lip	0.00115	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—FGFR3—cleft lip	0.00114	0.00114	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—FGF2—cleft lip	0.00114	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—FGFR1—cleft lip	0.00114	0.00114	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—FGFR1—cleft lip	0.00113	0.00113	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—NOS3—cleft lip	0.00113	0.00113	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—MYC—cleft lip	0.00112	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.00112	0.00112	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ABCA4—cleft lip	0.00112	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGF3—cleft lip	0.00112	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ARHGAP29—cleft lip	0.00111	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR3—cleft lip	0.00109	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—FGFR3—cleft lip	0.00109	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGF9—cleft lip	0.00109	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—FGFR1—cleft lip	0.00109	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—NOS3—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FGFR1—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGFR2—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGFR2—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR2—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—MTR—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—FGFR1—cleft lip	0.00108	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—FGFR3—cleft lip	0.00107	0.00107	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGF3—cleft lip	0.00107	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—FGFR2—cleft lip	0.00107	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FGFR1—cleft lip	0.00107	0.00107	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—FGFR3—cleft lip	0.00107	0.00107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGFR2—cleft lip	0.00106	0.00106	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—FGF2—cleft lip	0.00106	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGFR2—cleft lip	0.00106	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—MYC—cleft lip	0.00106	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGFR2—cleft lip	0.00106	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—FGFR1—cleft lip	0.00105	0.00105	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGF9—cleft lip	0.00104	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—FGF2—cleft lip	0.00103	0.00103	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—WNT9B—cleft lip	0.00103	0.00103	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—FGFR3—cleft lip	0.00103	0.00103	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—NOS3—cleft lip	0.00102	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FGFR3—cleft lip	0.00102	0.00102	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SLC19A1—cleft lip	0.00102	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—FGFR3—cleft lip	0.00102	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FGFR3—cleft lip	0.00101	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR1—cleft lip	0.00101	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGFR1—cleft lip	0.00101	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGFR1—cleft lip	0.00101	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—FGFR1—cleft lip	0.000998	0.000998	CbGpPWpGaD
Dabrafenib—BRAF—Disease—WNT3—cleft lip	0.000995	0.000995	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGFR1—cleft lip	0.000991	0.000991	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGFR1—cleft lip	0.000989	0.000989	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGFR1—cleft lip	0.000985	0.000985	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR2—cleft lip	0.000957	0.000957	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—cleft lip	0.000952	0.000952	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGFR3—cleft lip	0.000952	0.000952	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGFR3—cleft lip	0.000952	0.000952	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.000947	0.000947	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—FGFR3—cleft lip	0.000943	0.000943	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FGF2—cleft lip	0.000941	0.000941	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGFR3—cleft lip	0.000937	0.000937	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—FGF2—cleft lip	0.000935	0.000935	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—cleft lip	0.000935	0.000935	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGFR3—cleft lip	0.000931	0.000931	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—MYC—cleft lip	0.000918	0.000918	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGF10—cleft lip	0.000917	0.000917	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR1—cleft lip	0.000892	0.000892	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—FGF2—cleft lip	0.000882	0.000882	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGF10—cleft lip	0.000881	0.000881	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—WNT9B—cleft lip	0.000877	0.000877	CbGpPWpGaD
Dabrafenib—RAF1—Disease—WNT9B—cleft lip	0.000867	0.000867	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—MYC—cleft lip	0.000849	0.000849	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF7—cleft lip	0.000847	0.000847	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TCN2—cleft lip	0.000846	0.000846	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—FGF2—cleft lip	0.000844	0.000844	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—FGF2—cleft lip	0.000844	0.000844	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—cleft lip	0.000843	0.000843	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOG—cleft lip	0.000841	0.000841	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—FGF2—cleft lip	0.000831	0.000831	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC19A1—cleft lip	0.00083	0.00083	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—FGF2—cleft lip	0.000826	0.000826	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—WNT3—cleft lip	0.000816	0.000816	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF7—cleft lip	0.000813	0.000813	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—FGF2—cleft lip	0.000793	0.000793	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FGF2—cleft lip	0.000789	0.000789	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—MYC—cleft lip	0.000789	0.000789	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IRF6—cleft lip	0.000787	0.000787	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—FGF2—cleft lip	0.000785	0.000785	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ABCA4—cleft lip	0.000782	0.000782	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—FGF2—cleft lip	0.000782	0.000782	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF8—cleft lip	0.000781	0.000781	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—NOS3—cleft lip	0.000778	0.000778	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—MYC—cleft lip	0.000778	0.000778	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ABCA4—cleft lip	0.000772	0.000772	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF8—cleft lip	0.00075	0.00075	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGFR2—cleft lip	0.000736	0.000736	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGF2—cleft lip	0.000735	0.000735	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGF2—cleft lip	0.000735	0.000735	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGF2—cleft lip	0.000735	0.000735	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—FGF2—cleft lip	0.000729	0.000729	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—MYC—cleft lip	0.000724	0.000724	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGF2—cleft lip	0.000724	0.000724	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGF2—cleft lip	0.000722	0.000722	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGF2—cleft lip	0.000719	0.000719	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGFR2—cleft lip	0.000707	0.000707	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SLC19A1—cleft lip	0.000706	0.000706	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—WNT3—cleft lip	0.000697	0.000697	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000692	0.000692	CbGpPWpGaD
Dabrafenib—RAF1—Disease—WNT3—cleft lip	0.000688	0.000688	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TCN2—cleft lip	0.000687	0.000687	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGFR1—cleft lip	0.000686	0.000686	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGFR1—cleft lip	0.000659	0.000659	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SPRY2—cleft lip	0.000658	0.000658	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF7—cleft lip	0.000658	0.000658	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGF2—cleft lip	0.000651	0.000651	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ABCA4—cleft lip	0.000651	0.000651	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGFR3—cleft lip	0.000648	0.000648	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF3—cleft lip	0.000636	0.000636	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—MYC—cleft lip	0.000635	0.000635	CbGpPWpGaD
Dabrafenib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—cleft lip	0.000633	0.000633	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGFR3—cleft lip	0.000623	0.000623	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—FGFR1—cleft lip	0.000621	0.000621	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF9—cleft lip	0.00062	0.00062	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF3—cleft lip	0.000611	0.000611	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—MYC—cleft lip	0.000608	0.000608	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF8—cleft lip	0.000607	0.000607	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—WNT9B—cleft lip	0.000607	0.000607	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF9—cleft lip	0.000595	0.000595	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—FGF10—cleft lip	0.000592	0.000592	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTR—cleft lip	0.000586	0.000586	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TCN2—cleft lip	0.000585	0.000585	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOG—cleft lip	0.000582	0.000582	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—MTR—cleft lip	0.000577	0.000577	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC19A1—cleft lip	0.000557	0.000557	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ABCA4—cleft lip	0.000541	0.000541	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SUMO1—cleft lip	0.000539	0.000539	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.000528	0.000528	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF10—cleft lip	0.000523	0.000523	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC19A1—cleft lip	0.000516	0.000516	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF10—cleft lip	0.000502	0.000502	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—MYC—cleft lip	0.000501	0.000501	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—FGF2—cleft lip	0.000501	0.000501	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF3—cleft lip	0.000494	0.000494	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF7—cleft lip	0.000493	0.000493	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—WNT3—cleft lip	0.000482	0.000482	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF9—cleft lip	0.000482	0.000482	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FGF2—cleft lip	0.000481	0.000481	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTR—cleft lip	0.000476	0.000476	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TCN2—cleft lip	0.000462	0.000462	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF7—cleft lip	0.000461	0.000461	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPRY2—cleft lip	0.000461	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SPRY2—cleft lip	0.000455	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF7—cleft lip	0.000455	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF8—cleft lip	0.000455	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000452	0.000452	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTCH1—cleft lip	0.000447	0.000447	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.000447	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—FGFR1—cleft lip	0.000443	0.000443	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TCN2—cleft lip	0.000428	0.000428	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF8—cleft lip	0.000425	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF8—cleft lip	0.00042	0.00042	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGFR2—cleft lip	0.00042	0.00042	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF10—cleft lip	0.000407	0.000407	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTR—cleft lip	0.000406	0.000406	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR2—cleft lip	0.000403	0.000403	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGFR1—cleft lip	0.000391	0.000391	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTCH1—cleft lip	0.000382	0.000382	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR1—cleft lip	0.000376	0.000376	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF3—cleft lip	0.00037	0.00037	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGFR3—cleft lip	0.00037	0.00037	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF9—cleft lip	0.000361	0.000361	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR3—cleft lip	0.000355	0.000355	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF3—cleft lip	0.000346	0.000346	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF3—cleft lip	0.000342	0.000342	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF9—cleft lip	0.000338	0.000338	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF9—cleft lip	0.000333	0.000333	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000326	0.000326	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR2—cleft lip	0.000326	0.000326	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—FGF2—cleft lip	0.000324	0.000324	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC19A1—cleft lip	0.00032	0.00032	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTR—cleft lip	0.00032	0.00032	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF7—cleft lip	0.000319	0.000319	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPRY2—cleft lip	0.000319	0.000319	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—cleft lip	0.000314	0.000314	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS3—cleft lip	0.000313	0.000313	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF10—cleft lip	0.000305	0.000305	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR1—cleft lip	0.000304	0.000304	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTR—cleft lip	0.000296	0.000296	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF8—cleft lip	0.000294	0.000294	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TYMS—cleft lip	0.000292	0.000292	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR3—cleft lip	0.000287	0.000287	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGF2—cleft lip	0.000286	0.000286	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF10—cleft lip	0.000285	0.000285	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF10—cleft lip	0.000281	0.000281	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC19A1—cleft lip	0.000279	0.000279	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGF2—cleft lip	0.000274	0.000274	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TCN2—cleft lip	0.000265	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH1—cleft lip	0.000264	0.000264	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—cleft lip	0.000255	0.000255	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR2—cleft lip	0.000244	0.000244	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF3—cleft lip	0.000239	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF9—cleft lip	0.000234	0.000234	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TCN2—cleft lip	0.000231	0.000231	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR2—cleft lip	0.000228	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR1—cleft lip	0.000228	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR2—cleft lip	0.000226	0.000226	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF2—cleft lip	0.000222	0.000222	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—cleft lip	0.000219	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—cleft lip	0.000217	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR3—cleft lip	0.000215	0.000215	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000213	0.000213	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR1—cleft lip	0.000213	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR1—cleft lip	0.00021	0.00021	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR3—cleft lip	0.000201	0.000201	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR3—cleft lip	0.000199	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF10—cleft lip	0.000197	0.000197	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TYMS—cleft lip	0.000196	0.000196	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTR—cleft lip	0.000184	0.000184	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TYMS—cleft lip	0.000182	0.000182	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—cleft lip	0.000178	0.000178	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC19A1—cleft lip	0.000172	0.000172	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—cleft lip	0.000171	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF2—cleft lip	0.000166	0.000166	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTR—cleft lip	0.00016	0.00016	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—cleft lip	0.000159	0.000159	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR2—cleft lip	0.000158	0.000158	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF2—cleft lip	0.000156	0.000156	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF2—cleft lip	0.000154	0.000154	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—cleft lip	0.000153	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—cleft lip	0.000152	0.000152	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR1—cleft lip	0.000147	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—cleft lip	0.000145	0.000145	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TCN2—cleft lip	0.000142	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—cleft lip	0.000139	0.000139	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—cleft lip	0.00012	0.00012	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—cleft lip	0.000113	0.000113	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—cleft lip	0.000111	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—cleft lip	0.000108	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—cleft lip	0.000106	0.000106	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—cleft lip	0.000102	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—cleft lip	0.0001	0.0001	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTR—cleft lip	9.87e-05	9.87e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—cleft lip	9.85e-05	9.85e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—cleft lip	9.82e-05	9.82e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—cleft lip	8.58e-05	8.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—cleft lip	7.03e-05	7.03e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—cleft lip	6.87e-05	6.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—cleft lip	6.05e-05	6.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—cleft lip	5.98e-05	5.98e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—cleft lip	5.29e-05	5.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—cleft lip	3.69e-05	3.69e-05	CbGpPWpGaD
